These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Growth of niche CROs specializing in rare diseases. Increasing demand for biologics and biosimilars testing. Expansion into emerging markets. Top Drug Discovery Preclinical Cro Market Companies ...

The pharmaceutical industry has long played a key role in developing treatments for a wide range of medical conditions, particularly through biologics and biosimilars such as ... In recent years, in ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

To understand the class of drugs known as biosimilars, it is first necessary to understand the class of drugs described as biologics. Traditionally, biologics were derived through natural ...

The biosimilar approval was based on a comprehensive clinical data package, which included a double-blind, randomized, active-controlled phase 3 trial (ClinicalTrials.gov Identifier: NCT04757376 ...

Samsung Bioepis received approval for two biosimilars of denosumab that are interchangeable with Prolia and Xgeva. Ospomyv provided similar BMD increases as Prolia for women with osteoporosis in a ...

Basel, February 24, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US.From today, the ...

J&J seeks preliminary injunction over Samsung's sublicense deal with private label provider J&J says said sublicense deal would hurt its market share Samsung Bioepis launched its biosimilar in U.S ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number of FDA-approved biosimilars to 63. Forty-one of those biosimilars have ...